TABLE I.
Baseline subject demographic characteristics
| Subject group (n) | Healthy controls (22) | Mild/moderate (25) | Severe asthma (35) | Overall difference (P value) |
|---|---|---|---|---|
| Demographic | ||||
| Age (y) | 26.5 (23.3–33.5) | 24.6 (20.9–38.4) | 44.6 (34.4–55.2) | .0002* |
| Age at onset | n/a | 6 (2–13.5) | 5 (2–24) | .98 |
| Gender (male/female) | 12/10 | 6/19 | 10/25 | .06 |
| Race (white/AA/other) | 14/4/4 | 14/8/3 | 28/4/3 | .17 |
| BMI (kg/m2) | 23.4 (22.1–28.0) | 26.3 (23.1–29.8) | 31.7 (25.6–36.2) | .0002* |
| Serum IgE (kU/L) | 30 (15–60) | 179.5 (68.3–439.5) | 150 (27.3–458.5) | .004* |
| Baseline FEV1 (%p) | 99 (92.8–105.3) | 89 (81.5–97.5) | 52 (39–68) | <.0001* |
| Blood eosinophils (cells/mm3) | 100 (100–100) | 200 (100–300) | 200 (100–500) | .03* |
| Exhaled nitric oxide (ppb) | 20 (16–32) | 31 (21–58.25) | 38 (19–58.3) | .045* |
| LTRA use (yes/no) | n/a | 3/22 | 16/19 | .0001* |
| Anti-IgE therapy (yes/no) | n/a | 0/25 | 9/26 | .008* |
| ICS use | n/a | 16/25 | 35/35 | <.0001* |
Discrete data were analyzed using the Pearson χ2 test or Fisher exact test, and continuous data were analyzed using the Kruskal-Wallis test.
AA, African American; n/a, not applicable; %p, percent predicted; ppb, parts per billion.
*
P < .05.